Aidoc

Executive Summary

Aidoc is a leading Israeli AI-driven medtech company specializing in advanced imaging analysis for radiology, cardiology, neurovascular, and other specialties. Its proprietary aiOS™ platform hosts a suite of FDA-cleared algorithms that automatically detect and triage critical findings across CT, MRI, X-ray, and ultrasound studies, integrating seamlessly with hospital IT systems. Founded in 2020 and operating in the commercial stage, Aidoc has raised $150 million and employs 200-500 people. The company focuses on improving workflow efficiency, diagnostic accuracy, and patient outcomes through real-time AI-augmented imaging. With a strong clinical evidence base and growing adoption in health systems, Aidoc is positioned as a key player in the AI medical imaging market, which is poised for significant expansion as healthcare digitization accelerates. Aidoc’s commercial traction and regulatory clearances provide a solid foundation, though the private nature of the company limits visibility into financial metrics. The imaging AI market is competitive, with players like Zebra Medical and Viz.ai, but Aidoc’s comprehensive multi-modality platform and focus on workflow integration differentiate it. The company is likely to continue expanding its algorithm portfolio into new clinical areas and geographies, driving growth. However, execution risks include regulatory hurdles, reimbursement challenges, and competition. Overall, Aidoc shows strong potential for value creation in the near to medium term.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for New Cardiovascular Algorithm70% success
• Q4 2026Strategic Partnership with a Major US Hospital Network65% success
• Q1 2027European Expansion with CE Mark Approvals55% success